De Novo device
DermaSensor
Dermasensor, Inc. · Software-Aided Adjunctive Diagnostic Device For Use By Physicians On Lesions Suspicious For Skin Cancer (QZS, Class II) · First FDA decision Jan 12, 2024, newest Jan 12, 2024Skin cancer
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
Breakthrough-designated
Device trials
3
Naming "DermaSensor"
MAUDE reports
11
Brand "DermaSensor", since 2015
PubMed studies
8
Mentioning "DermaSensor"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing DermaSensor
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 1 of 1 decisions filed under this name.
- DermaSensorNew device typeBreakthroughDe Novo
DEN230008 · Decided Jan 12, 2024 · 344 days after receipt
Device type: Software-Aided Adjunctive Diagnostic Device For Use By Physicians On Lesions Suspicious For Skin Cancer (QZS) · General & Plastic Surgery
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "DermaSensor", any status and sponsor, newest update first.
- Skin Cancer Detection in Primary Care With and Without DermaSensorPivotal-lookingNot yet recruiting
DermaSensor, Inc.Not on our public-company list
NCT07940036 · 200 participants (planned) · Start Nov 10, 2026 · Primary completion Jun 2028
Device: DermaSensor · For: Skin Cancer; Basal Cell Cancer; Squamous Cell Carcinoma and 4 more
Sites: St Louis, Missouri
DermaSensor, Inc.Not on our public-company list
NCT06690086 · 1,028 participants · Start Aug 17, 2020 · Primary completion Dec 9, 2021
Device: DermaSensor Device Use · For: Skin Cancer
Sites: Rochester, Minnesota
DermaSensor, Inc.Not on our public-company list
NCT06666790 · 396 participants (planned) · Start Oct 8, 2024 · Primary completion Apr 11, 2027
Device: Scan with elastic scattering spectroscopy device to assess risk of malignancy · For: Melanoma, Skin
Sites: New Smyrna Beach, Florida; Morehead City, North Carolina
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "DermaSensor", and for the whole product code for context.
This brand
11 reports: 11 malfunction, 0 injury, 0 death
Whole product code QZS
11 reports: 11 malfunction, 0 injury, 0 death
Newest reports for this brand
- DERMASENSORMalfunction
3017254-2025-00011 · Received Feb 9, 2026
Device type: Software-Aided Adjunctive Diagnostic Device For Use By Physicians On Lesions Suspicious For Skin Cancer (QZS)
Device problem as coded: Nonstandard Device; Product Quality Problem; Manufacturing, Packaging or Shipping Problem
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
- DERMASENSORMalfunction
3017254-2025-00010 · Received Feb 2, 2026
Device type: Software-Aided Adjunctive Diagnostic Device For Use By Physicians On Lesions Suspicious For Skin Cancer (QZS)
Device problem as coded: Nonstandard Device; Product Quality Problem; Manufacturing, Packaging or Shipping Problem
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
- DERMASENSORMalfunction
3017254-2025-00002 · Received Jan 27, 2026
Device type: Software-Aided Adjunctive Diagnostic Device For Use By Physicians On Lesions Suspicious For Skin Cancer (QZS)
Device problem as coded: Nonstandard Device; Product Quality Problem; Manufacturing, Packaging or Shipping Problem
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
2 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "DermaSensor"[tiab]. The summary above synthesizes these.
- Artificial intelligence in melanoma diagnosis: ethical considerations and clinical implementation.
Verma KK, Grabow KM, Koch RS, et al. · Proc (Bayl Univ Med Cent) · 2025
- Primary Care Physician Use of Elastic Scattering Spectroscopy on Skin Lesions Suggestive of Skin Cancer.
Merry SP, Croghan IT, Dukes KA, et al. · J Prim Care Community Health · 2025Multicenter Study, Validation Study
- Learnings from the first AI-enabled skin cancer device for primary care authorized by FDA.
Venkatesh KP, Kadakia KT, Gilbert S · NPJ Digit Med · 2024
- Multicenter prospective blinded melanoma detection study with a handheld elastic scattering spectroscopy device.
Hartman RI, Trepanowski N, Chang MS, et al. · JAAD Int · 2024
- Artificial Intelligence in Dermatology: A Comprehensive Review of Approved Applications, Clinical Implementation, and Future Directions.
Nahm WJ, Sohail N, Burshtein J, et al. · Int J Dermatol · 2025Review
- Enhancing Diagnostic Precision in Primary Care: A Multireader Multicase (MRMC) Study of an AI-Powered Handheld Elastic Scattering Spectroscopy Device for Informed Referral Decisions in Melanoma Evaluation.
Seiverling EV, Shah A, Weinstock MA, et al. · J Clin Aesthet Dermatol · 2025
- Artificial Intelligence in Oncology: A Comprehensive Cross-Cancer Translational Readiness Analysis Across 18 Malignancies.
Kuchana SK, Repalle UK, Alahari NV, et al. · Cancers (Basel) · 2026Review
- Current landscape of AI Regulation in Dermatology.
Motavaf M, Raza D, Frye W, et al. · J Am Acad Dermatol · 2026
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.